

1 **The Lancet peer reviewers and the COVID-19 pandemic**

2

3 Gwinyai Masukume<sup>1,\*</sup>, Victor Grech<sup>2</sup>

4

5 <sup>1</sup>Tipperary, Munster, Ireland

6 <sup>2</sup>Academic Department of Paediatrics, Medical School, Mater Dei Hospital, Msida, Malta

7 \*parturitions@gmail.com

8

9

10

11

12

13

14

15

16

17

18

19

20

21 **Abstract**

22 Introduction:

23 Peer review is paramount to the scholarly article paradigm, helping to ensure the integrity and  
24 credibility of research. *The Lancet* played a crucial role in disseminating key information on  
25 the COVID-19 pandemic, publishing early clinical descriptions, risk factors for death, and  
26 effectiveness of measures like physical distancing and masks. Notably, *The Lancet* was the  
27 world's most cited journal for COVID-19 research, emphasising its significant impact on  
28 disseminating critical findings during the pandemic.

29 Methods:

30 Geographic data for *The Lancet's* peer reviewers in 2019 (pre-pandemic) and 2020  
31 (pandemic) were analysed at the country level, ranking reviewer countries. A test of  
32 proportions compared reviewer numbers between the years.

33 Results:

34 In 2020, China emerged as one of the top ten reviewer countries for the first time, with a  
35 significant increase from 1% (25 of 1843) in 2019 to 3% (54 of 1850),  $p=0.001$ . Italy also  
36 entered the top five reviewer countries, rising from 4% (67) to 5% (90),  $p=0.065$ . Reviewers  
37 from Africa 43 (2%) and South America 31 (2%) represented their continents in 2020. The  
38 top ten reviewer nations for *The Lancet* in 2020 largely mirrored the top ten countries in  
39 global COVID-19 research output.

40 Conclusion:

41 During the COVID-19 pandemic's acute phase in 2020, *The Lancet*, the world's most cited  
42 journal for COVID-19 research, featured peer reviewers who were largely representative of  
43 global COVID-19 research output. Notably, reviewers from China, the first country affected

44 by COVID-19, increased significantly. However, underrepresentation of some continents  
45 persisted. To foster global idea exchange and enhance pandemic preparedness, research  
46 capacity worldwide must expand, broadening the reviewer pool—a vital step given  
47 uncertainties in future pandemic geographic origin.

48

49 **Key words**

50 COVID-19, peer review, pandemic, academic medicine, journalology

51

52

53

54

55

56

57

58

59

60

61

62

63

64 *The Lancet* played a crucial role in disseminating key information related to the COVID-19  
65 pandemic which in turn informed global practice. For instance *The Lancet* published early on,  
66 in January 2020, one of the first descriptions of the clinical features of this pandemic.<sup>1</sup>  
67 Similarly, *The Lancet* published an early paper, in March 2020, describing the risk factors for  
68 death in hospitalised patients.<sup>2</sup> Indeed *The Lancet* was the world's most cited journal for  
69 COVID-19 research.<sup>3</sup> These research articles were widely shared and discussed in the news  
70 and on social media. An example was a paper that analysed how physical distancing, face  
71 masks, and eye protection reduced disease spread.<sup>4</sup> Another example is a paper that looked  
72 into COVID-19 treatment with hydroxychloroquine or chloroquine that was subsequently  
73 discovered to be based on false data and hence retracted.<sup>5</sup>

74 Peer review is critical to the scholarly article paradigm.<sup>6</sup> It is thus important to explore how  
75 peer review changed at *The Lancet* during the acute pandemic phase, in 2020,<sup>7</sup> since this  
76 journal will likely play an equally central role in the publication of impactful findings during  
77 future pandemics.


78 We analysed data for over 3600 of *The Lancet's* peer reviewers for the years 2019<sup>8</sup> (pre-  
79 pandemic) and 2020<sup>9</sup> (pandemic). Because the data was publicly available ethics review was  
80 not required. A two-sample test of proportions in Stata version 17BE (StataCorp LP College  
81 Station, TX) was used to compare the proportion of reviewers between the years. In 2020  
82 China entered the top ten reviewer countries for the first time in comparison to pre-pandemic  
83 data (figure 1), while Italy entered the top five reviewer countries for the first time (figure  
84 2).<sup>10</sup> China increased its number of reviewers from 1% (25 of 1843) in 2019 to 3% (54 of  
85 1850) in 2020,  $p=0.001$ . For Italy, the numbers were 4% (67) and 5% (90) respectively,  
86  $p=0.065$ . These findings were consistent with the global trajectory of the severe acute  
87 respiratory syndrome coronavirus 2 (SARS-CoV-2), with an early peak in COVID-19 papers  
88 from China and a subsequent rise in papers from Italy as the virus spread.<sup>11</sup>

89 The top two reviewer countries were the USA and the UK which accounted for 48% (884) of  
90 reviewers in 2019 and 45% (841) in 2020,  $p=0.13$ . This was consistent with the earlier pre-  
91 pandemic pattern.<sup>10</sup> With the exception of China in 2020, the top ten nations in terms of the  
92 number of peer reviewers remained the same. These included France, Germany, and Canada,  
93 all of which are members of the Group of Seven (G7), the largest advanced economies, along  
94 with the aforementioned USA, UK, and Italy.

95 With two exceptions, the top ten nations by peer reviewer country of origin for *The Lancet* in  
96 2020 were identical to the top ten countries by global COVID-19 research output in 2020.<sup>12</sup>  
97 These two nations were Spain and India.

98 Reviewers from Africa in 2020 were 43 (2%), 19 of them from South Africa, and there were  
99 31 (2%) from South America, 23 of them from Brazil. These data were in line with pre-  
100 pandemic reviewer data.


101 In conclusion, with a notable increase from China, the first country to be affected by COVID-  
102 19, *The Lancet* peer reviewers during the acute phase of the COVID-19 pandemic were  
103 largely representative of the global COVID-19 research output. Reviewer numbers also  
104 reflected the current underrepresentation of some continents in global research. Prior to the  
105 next pandemic, it might be useful to recruit reviewers from underrepresented global regions  
106 in order to foster global idea exchanges and potentially create a more effective response to  
107 such crises but this may be hindered by smaller numbers – there may be fewer eligible  
108 researchers in these regions so that the current underrepresentation simply reflects this,  
109 posing a reviewer recruiting challenge to all journals. It is crucial to expand the capacity of  
110 research worldwide and, consequently, the pool of reviewers. As the geographic origin of the  
111 next pandemic remains uncertain, a more inclusive approach is essential.



112

113 **Figure 1: Number and location of *The Lancet* peer reviewers, 2020**

114



115

116 **Figure 2: Number and location of *The Lancet* peer reviewers, 2019**

117

118 **Competing interests**

119 We declare no competing interests.

120

121 **Funding**

122 No funding was received for this work.

123

## 124 **References**

- 125 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients  
126 infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.
- 127 2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for  
128 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.  
129 *Lancet*. 2020;395(10229):1054-62.
- 130 3. Kambhampati SBS, Vasudeva N, Vaishya R, Patralekh MK. Top 50 cited articles on  
131 Covid-19 after the first year of the pandemic: A bibliometric analysis. *Diabetes Metab Syndr*.  
132 2021;15(4):102140.
- 133 4. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ. Physical distancing,  
134 face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and  
135 COVID-19: a systematic review and meta-analysis. *Lancet*. 2020;395(10242):1973-87.
- 136 5. Mehra MR, Desai SS, Ruschitzka F, Patel AN. ~~RETRACTED~~: Hydroxychloroquine  
137 or chloroquine with or without a macrolide for treatment of COVID-19: a multinational  
138 registry analysis. *Lancet*. 2020.
- 139 6. Ben Messaoud K, Schroter S, Richards M, Gayet-Ageron A. Analysis of peer  
140 reviewers' response to invitations by gender and geographical region: cohort study of  
141 manuscripts reviewed at 21 biomedical journals before and during covid-19 pandemic. *Bmj*.  
142 2023;381:e075719.
- 143 7. Callaway E, Ledford H, Viglione G, Watson T, Witze A. COVID and 2020: An  
144 extraordinary year for science. *Nature*. 2020;588(7839):550-2.



- 145 8. The Editors of The Lancet. Thank you to The Lancet's reviewers of 2019. The Lancet.  
146 2020;395(10226):769.
- 147 9. The Editors of The Lancet. Thank you to The Lancet's reviewers of 2020. The Lancet.  
148 2021;397(10277):864.
- 149 10. Masukume G, Grech V. The Lancet peer reviewers: global pattern and distribution.  
150 Lancet. 2018;391(10140):2603-4.
- 151 11. Else H. How a torrent of COVID science changed research publishing - in seven  
152 charts. Nature. 2020;588(7839):553.
- 153 12. Wagner CS, Cai X, Zhang Y, Fry CV. One-year in: COVID-19 research at the  
154 international level in COVID-19 data. PLoS One. 2022;17(5):e0261624.